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Abstract
Aims/hypothesis Glucosamine, generated during hypergly-
caemia, causes insulin resistance in different cells. Here we
sought to evaluate the possible role of endoplasmic
reticulum (ER) stress in the induction of insulin resistance
by glucosamine in skeletal muscle cells.
Methods Real-time RT-PCR analysis, 2-deoxy-D-glucose
(2-DG) uptake and western blot analysis were carried out
in rat and human muscle cell lines.
Results In both rat and human myotubes, glucosamine
treatment caused a significant increase in the expression of
the ER stress markers immunoglobulin heavy chain-binding
protein/glucose-regulated protein 78 kDa (BIP/GRP78 [also
known as HSPA5]), X-box binding protein-1 (XBP1) and
activating transcription factor 6 (ATF6). In addition,
glucosamine impaired insulin-stimulated 2-DG uptake in
both rat and human myotubes. Interestingly, pretreatment of
both rat and human myotubes with the chemical chaperones
4-phenylbutyric acid (PBA) or tauroursodeoxycholic acid
(TUDCA), completely prevented the effect of glucosamine
on both ER stress induction and insulin-induced glucose
uptake. In both rat and human myotubes, glucosamine
treatment reduced mRNA and protein levels of the gene
encoding GLUT4 and mRNA levels of the main regulators
of the gene encoding GLUT4 (myocyte enhancer factor 2 a
[MEF2A] and peroxisome proliferator-activated receptor-γ
coactivator 1α [PGC1α]). Again, PBA or TUDCA pre-
treatment prevented glucosamine-induced inhibition of
GLUT4 (also known as SLC2A4), MEF2A and PGC1α
(also known as PPARGC1A). Finally, we showed that
overproduction of ATF6 is sufficient to inhibit the
expression of genes GLUT4, MEF2A and PGC1α and that
ATF6 silencing with a specific small interfering RNA is
sufficient to completely prevent glucosamine-induced inhi-
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bition of GLUT4, MEF2A and PGC1α in skeletal muscle
cells.
Conclusions/interpretation In this work we show that
glucosamine-induced ER stress causes insulin resistance in
both human and rat myotubes and impairs GLUT4
production and insulin-induced glucose uptake via an
ATF6-dependent decrease of the GLUT4 regulators MEF2A
and PGC1α.
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Abbreviations
2-DG 2-Deoxy-D-glucose
ATF6 Activating transcription factor 6
BIP/GRP78 Immunoglobulin heavy chain-binding
protein/glucose-regulated protein 78 kDa
ChIP Chromatin immunoprecipitation assay
eIF2α Eukaryotic translation initiation factor 2α
ER Endoplasmic reticulum
GEF GLUT4 enhancer factor
GlcN Glucosamine
GFAT Glutamine:fructose-6-phosphate
amidotransferase
HBP Hexosamine biosynthetic pathway
HG High glucose
MEF2A Myocyte enhancer factor 2 a
MnTBAP Mn(III)tetrakis(4-benzoic acid)
porphyrin chloride
NAC N-Acetyl-cysteine
PBA 4-Phenylbutyric acid
PERK Double-stranded RNA-activated
protein kinase-like ER kinase
PGC1α Peroxisome proliferator-activated
receptor-γ coactivator 1 α
PUGNAc O-(2-Acetamido-2-deoxy-D-glucopy-
ranosylidenamino)N-phenylcarbamate
SHP Orphan nuclear receptor small
heterodimer partner
siRNA Small interfering RNA
Thap Thapsigargin
TUDCA Tauroursodeoxycholic acid
UPR Unfolded protein response
XBP-1s X-box binding protein-1, spliced active
form
XBP-1t X-box binding protein-1, total form
Introduction
The endoplasmic reticulum (ER) is the principal site of
protein synthesis, and together with the Golgi apparatus it
facilitates transport and release of correctly folded proteins.
Under conditions of cellular stress leading to an impairment
of ER function, proteins are unable to fold properly and
accumulate in the ER lumen. It is because of these unfolded
or misfolded proteins that the ER has evolved a coping
system known as the unfolded protein response (UPR) [1, 2].
Cellular stresses that may elicit UPR activation in-
clude glucose and energy deprivation, increased protein
synthesis, inhibition of protein glycosylation and imbal-
ance of ER calcium levels [3, 4]. In mammalian cells, at
least four functionally distinct responses have been
identified and three ER-resident transmembrane proteins
have been described as primary sensors and transducers of
the UPR: the double-stranded RNA-activated protein
kinase-like ER kinase (PERK), inositol requiring-1, and
activating transcription factor 6 (ATF6) [5–7]. The first
response, mediated by PERK, is translational attenuation,
to reduce the load of new protein synthesis and prevent
further accumulation of unfolded proteins [8]. The second
response is upregulation of genes encoding ER chaperone
proteins such as the immunoglobulin heavy chain-binding
protein/glucose-regulated protein 78 kDa (BIP/GRP78)
and the glucose-regulated protein 94 kDa, to increase the
ER protein-folding capacity [7, 9]. The third response is
transcriptional activation of genes involved in the degra-
dation of misfolded protein in the ER by the ubiquitin–
proteasome system, called ER-associated degradation
[10]. The fourth response is apoptosis, which occurs when
severe and prolonged ER stress impairs ER functions, to
protect the organism by eliminating the damaged cells [4].
ER stress plays an important role in several human
diseases, including type 2 diabetes; indeed, recent studies
reported that ER stress is involved in both pancreatic beta
cell dysfunction [11–13] and peripheral insulin resistance
[14, 15].
While the consequences of ER stress have been widely
studied in adipose tissue and liver, ER stress in skeletal
muscle, the major site of glucose disposal, has not received
equal attention. The hexosamine biosynthetic pathway
(HBP) is a minor glucose metabolic pathway that metabolises
∼3% of glucose entering the cell, and the final product of this
pathway, UDP-N-acetylglucosamine, as other nucleotide
hexosamines, is used in the ER as substrate for protein
glycosylation [16, 17]. Although quantitatively using a
small fraction of glucose, HBP is an important contributor
to the insulin-resistant state. Several studies have shown,
indeed, that chronic exposure to glucosamine (GlcN), a
precursor of the HBP, impairs insulin responsiveness, thus
contributing to the formation of an insulin-resistant state in
cultured human skeletal muscle cells and rat adipocytes [17]
as well as in vivo [18]. However, the precise mechanisms by
which GlcN induces insulin resistance have not been
conclusively established in these studies.
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Methods
Materials DMEM, FBS, FCS, L-glutamine and BSA were
from Invitrogen (Paisley, UK). Thapsigargin (Thap), GlcN,
4-phenylbutyric acid (PBA) and N-acetyl-cysteine (NAC),
were from Sigma-Aldrich (St Louis, MO, USA). Mn(III)
tetrakis(4-benzoic acid) porphyrin chloride (MnTBAP) and
tauroursodeoxycholic acid (TUDCA) were from Calbio-
chem (San Diego, CA, USA). Other reagents were as
follows: Ultroser G (Pall Biosepra, Cergy, France), 2-
deoxy-D-[14C]glucose (2-DG) (Perkin Elmer, Waltham,
MA, USA), insulin (Novo Nordisk, Bagsværd, Denmark),
GLUT4 (Abcam, Cambridge, UK), myocyte enhancer
factor 2 a (MEF2A), peroxisome proliferator-activated
receptor-γ coactivator 1α (PGC1α), eukaryotic translation
initiation factor 2α (eIF2α) and phospho-eIF2α antibodies
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), small
interfering RNA (siRNA) and siPORT NeoFX Transfection
Agent (Applied Biosystems, Carlsbad, CA, USA)
Cell culture procedures and 2-DG uptake Human cell
cultures from lean individuals were established as described
previously [19–21] (Table 1). Cells were cultured in
DMEM supplemented with 2% (vol./vol.) FCS, 2% (vol./
vol.) Ultroser G and antibiotics. Human myotubes were
allowed to differentiate under physiological conditions of
insulin (25 pmol/l) and glucose (5.5 mmol/l) for 4 days. L6
rat skeletal muscle myoblasts were grown in DMEM
supplemented with 10% (vol./vol.) FBS, 2 mmol/l L-
glutamine and antibiotics. L6 myotubes were allowed to
differentiate as described previously [22]. 2-DG uptake was
measured as reported previously [23].
Real-time RT-PCR and western blot analysis Total RNA
extraction, cDNA synthesis and real-time RT-PCR analysis
were performed as described previously [24]. Primer sequen-
ces are in Electronic supplementary material (ESM) Table 1.
Cell lysates and immunoblotting were carried out as described
previously [22]. Antibodies against GLUT4, phospho-eIF2α
and eIF2α were used for detection of proteins.
Chromatin immunoprecipitation (ChIP) assay ChIP assays
were performed as reported [25]. Vehicle- or reagent-treated
myotubes were fixed with 1% (vol./vol.) formaldehyde at
37°C. The fixed cells were lysed in a SDS lysis buffer (1%
[wt/vol.] SDS, 10 mmol/l EDTA and 50 mmol/l TRIS–HCl,
pH 8.1), incubated on ice, and sonicated to shear DNA.
Sheared chromatin samples were taken as input control or
used for immunoprecipitation with anti-MEF2A, anti-
PGC1α or non-immune antibodies. DNA fragments were
recovered and were subjected to real-time RT-PCR ampli-
fication by using specific primers for the analysed regions.
Atf6 siRNA-mediated knockdown Cells were transfected
with 5 nmol/l of siRNA negative control and Atf6 siRNA
(GCUUGUCAGUCACGAAAGAtt) and antisense
(UCUUUCGUGACUGACAAGCag) according to the
manufacturer’s recommendations and processed 48 h after
transfection.
Statistical procedures Data were analysed with Statview
software (Abacus Concepts, Piscataway, NJ, USA) by one-
factor analysis of variance. p<0.05 was considered statis-
tically significant.
Results
To investigate the role of GlcN in ER stress induction,
differentiated L6 skeletal muscle cells were treated with
different concentrations of GlcN. The classic ER stress
inducer Thap, an inhibitor of sarcoplasmic/ER calcium-
transporting ATPases, was used as a control of ER stress
induction [2]. In L6 myotubes, Thap induced a 17-fold
increase of the chaperone Bip/grp78 (also known as Hspa5)
mRNA (Fig. 1a), indicating that our cellular model was
sensitive to ER stress. Bip/grp78 mRNA levels were
increased also by GlcN, with a maximal expression
observed at 10 mmol/l GlcN for 24 h (Fig. 1b). Interest-
ingly, pretreatment of cells with azaserine, a non-specific
but commonly used inhibitor of the glutamine:fructose-6-
phosphate amidotransferase (GFAT) [26, 27], the rate-
limiting enzyme of the HBP, prevented high glucose
(HG)-induced ER stress (ESM Fig. 1a). In addition,
treatment of cells with the peptide O-acetylglucosamine-
β-N-acetylglucosaminidase inhibitor O-(2-acetamido-2-de-
oxy-D-glucopyranosylidenamino)N-phenylcarbamate
(PUGNAc), did not increase Bip/grp78 mRNA levels,
suggesting that enhanced O-linked glycosylation was not
Table 1 Biochemical features of the euglycaemic individuals (n=5)
Variable Value
Age (years) 55.3±2.2
BMI (kg/m2) 23.0±1.1
Fasting plasma glucose (mmol/l) 5.4±0.2
Fasting plasma insulin (pmol/l) 35.2±7.8
HbA1c (%) 5.6±0.1
Values represent means ± SD
Muscle biopsies were obtained from the vastus lateralis muscle of five
lean individuals by needle biopsy under local anaesthesia [19].
Subjects had normal glucose tolerance and no family history of
diabetes. Individuals gave written, informed consent, and the local
ethics committee of Funen and Vejle county (Denmark) approved the
study
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responsible for the induction of ER stress (ESM Fig. 1a).
To evaluate whether GlcN-induced ER stress could be
mediated by oxidative stress, L6 myotubes were pretreated
with two anti-oxidants, the glutathione precursor NAC and
the superoxide dismutase mimetic MnTBAP. Pretreatment
of cells with both NAC and MnTBAP did not affect GlcN-
induced Bip/grp78 mRNA increase, suggesting that GlcN-
induced ER stress was not dependent on oxidative stress in
skeletal muscle cells (Fig. 1b). Then we evaluated the
effects of different concentrations of GlcN on ATP
intracellular levels. GlcN depleted the ATP pool only at
the highest concentrations, suggesting that GlcN-induced
ER stress was not dependent on ATP depletion in skeletal
muscle cells (ESM Fig. 2). As expected, xylose did not
induce a Bip/grp78 mRNA increase, even at high concen-
trations (Fig. 1b), thus excluding an osmotic stress effect
caused by treatments. Time course analysis with 7.5 mmol/
l GlcN showed that Bip/grp78 expression was significantly
increased as early as 2 h after the treatment and was
elevated up to 16 h (Fig. 1c). To investigate whether chemical
chaperones could prevent GlcN-induced ER stress, we
analysed Bip/grp78 mRNA in L6 myotubes treated with
GlcN in the presence of either 10 mmol/l PBA, a low
molecular weight non-specific chemical chaperone known to
stabilise protein conformation and to improve ER folding
capacity [28], or 5 mmol/l TUDCA, a bile acid derivative that
also modulates ER function [28]. Both PBA and TUDCA
almost completely prevented the effect of GlcN on Bip/grp78
mRNA (Fig. 1d). These data suggest that GlcN is able to
induce ER stress in skeletal muscle cells and that this effect is
prevented by chemical chaperones.
To verify whether GlcN was able to induce UPR
activation, L6 myotubes were treated with GlcN or Thap
and different markers of UPR activation were analysed. The
mRNA levels of the gene (Xbp1) encoding the spliced
active form of the X-box binding protein-1 (XBP-1; Xbp1
s) increased significantly following both Thap (Fig. 2a) and
GlcN treatments (Fig. 2b). Time course experiments
showed that the increase of Xbp1 s peaked at 8 h of GlcN
treatment and remained higher than basal level up to 24 h
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Fig. 1 GlcN induces BIP/GRP78 in L6 myotubes. a–d Bip/grp78
mRNA was determined by real-time RT-PCR analysis of total RNA
isolated from myotubes, using Gapdh as internal standard. mRNA
levels in treated cells are relative expression units (REU) to those in
control (C; mean ± SD; n=8). ***p<0.001. a L6 cells were treated
with 0.5 µmol/l Thap for 30 min, followed by 24 h without Thap.
b L6 cells were pretreated or not with 5 mmol/l NAC or with 1 mg/ml
MnTBAP for 2 h and then cultured in the presence of GlcN or xylose,
as indicated, for 24 h. c Time course of Bip/grp78 mRNA in L6 cells
cultured with 7.5 mmol/l GlcN for the indicated times. d L6 cells were
pretreated or not for 1 h with 10 mmol/l PBA or 5 mmol/l TUDCA
and then treated with 7.5 mmol/l GlcN for 24 h
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(Fig. 2b). In addition, also the mRNA levels of the genes
encoding the total form of XBP-1 (Xbp1 t) and ATF6 (Atf6)
were significantly increased upon both Thap (Fig. 2c,e) and
GlcN treatments (Fig. 2d,f). Furthermore, phosphorylation
of eIF2α was evident as early as 30 min after both GlcN
and Thap treatment, and it persisted up to 24 h following
GlcN treatment (Fig. 2g). These data suggest that GlcN
caused UPR activation in L6 myotubes.
To investigate the effect of GlcN-induced ER stress on
the insulin sensitivity of skeletal muscle cells, insulin-
induced glucose uptake was evaluated in L6 myotubes
treated with GlcN for 24 h. GlcN treatment reduced the
capability of L6 cells to take up the glucose analogue 2-DG
upon insulin stimulation, compared with control cells
(Fig. 3a). Similar results were obtained when cells were
treated with Thap (data not shown) and HG (ESM Fig. 1b).
To verify the hypothesis that GlcN and HG may impair
glucose uptake in L6 cells through ER stress induction, we
analysed insulin-induced glucose uptake in cells treated
with either GlcN or HG in the presence of PBA or TUDCA.
Interestingly, both PBA and TUDCA prevented GlcN
(Fig. 3a) and HG (ESM Fig. 1b) effects on insulin-
stimulated glucose uptake, suggesting that ER stress caused
insulin resistance in skeletal muscle cells.
We then evaluated GlcN effects on the expression of
GLUT4, since it is the main glucose transporter responsible
for insulin-mediated glucose uptake in muscle [29]. Time
course analysis showed that Glut4 (also known as Slc2a4)
mRNA levels were significantly decreased as early as 6 h
after GlcN treatment, and were reduced by about 50% after
16 h of treatment (Fig. 3b). Glut4 mRNA levels did not show
any significant variation when L6 myotubes were treated
with GlcN in the presence of PBA (Fig. 3c). In addition, the
GlcN-dependent decrease of Glut4 mRNA expression was
paralleled by a similar reduction of GLUT4 protein levels
and this was also prevented by pretreatment with PBA
(Fig. 3d). As for GlcN, both Thap (data not shown) and HG
treatment (ESM Fig. 1c), induced a significant decrease of
both GLUT4 protein and mRNA levels compared with
control cells. These data indicated that GlcN and HG reduced
Glut4 expression through the induction of ER stress.
Actinomycin D treatment did not further decrease Glut4
mRNA upon GlcN treatment, suggesting that GlcN-induced
ER stress determined a transcriptional inhibition of Glut4 in
skeletal muscle cells, without affecting its mRNA stability
(data not shown). To gain further insight into the mecha-
nisms leading to Glut4 reduced transcription, we analysed
the expression of genes relevant to Glut4 transcriptional
regulation by real-time RT-PCR analysis. Time course
experiments showed that GlcN caused a significant reduc-
tion of Mef2a mRNA expression as early as 6 h after the
treatment, with a 60% reduction at 16 h (Fig. 4a). Similarly,
MEF2A coactivator Pgc1α (also known as Ppargc1a) was
reduced by 50% after 16 h of treatment compared with
control cells (Fig. 4c). As for GlcN, both Thap (data not
shown) and HG treatment (ESM Fig. 1c) induced a
significant decrease of Mef2a and Pgc1α expression levels.
L6 cells treated with GlcN in the presence of PBA
exhibited no differences in the mRNA levels of both Mef2a
(Fig. 4b) and Pgc1α (Fig. 4d) compared with control cells,
confirming that also Mef2a and Pgc1α reduced expression
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Fig. 2 GlcN induces UPR activation in L6 myotubes. a–g L6 cells
were treated with 0.5 µmol/l Thap for 30 min, followed by 24 h
without Thap, or with 7.5 mmol/l GlcN for the indicated times (a–f).
Xbp1 s (a, b), Xbp1 t (c, d) and Atf6 (e, f) mRNAs in treated cells are
relative expression units (REU) to those in control (C; mean ± SD; n=
7) and were determined by real-time RT-PCR analysis, using Gapdh
as internal standard. *p<0.05; ***p<0.001. g L6 cells treated with
0.5 µmol/l Thap for 30 min, followed by 24 h without Thap (left), or
with 7.5 mmol/l GlcN (right) for the indicated times, were solubilised
and equal amounts of proteins (80 µg per sample) were analysed by
western blotting using phospho-eIF2α Ser51 and eIF2α specific
antibodies (n=5)
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was dependent on GlcN-induced ER stress. To establish
whether the reduction of Mef2a and Pgc1α expression
induced by ER stress was paralleled by a reduced binding
of these two proteins to the GLUT4 promoter, we
performed ChIP and re-ChIP experiments in L6 cells
treated with GlcN. MEF2A binding to GLUT4 promoter
showed a 60% decrease upon GlcN treatment compared
with control cells (Fig. 4e). Similarly, PGC1α indirect
binding to GLUT4 promoter measured by re-ChIP assay
was reduced by 40% upon GlcN treatment compared with
control cells (Fig. 4f). These data indicate that GlcN-
induced ER stress causes the transcriptional inhibition of
Glut4, at least in part by reducing both Mef2a and Pgc1α
mRNA levels and their binding to the GLUT4 promoter.
To understand the mechanisms involved in the transcrip-
tional inhibition ofGlut4, Mef2a and Pgc1α by ER stress, we
sought to evaluate the role of Atf6, a gene whose expression
has been reported to be upregulated during ER stress and may
cause inhibition of gene expression via upregulation of the
orphan nuclear receptor small heterodimer partner (SHP) in
pancreatic beta cells [30]. To test the hypothesis that the
overexpression of ATF6 is sufficient to impair GLUT4
expression, we generated L6 cell lines stably overexpressing
Atf6 (Fig. 5a). In Atf6-overexpressing cells, Glut4 mRNA
levels were reduced by 60% in basal condition (Fig. 5b), and
were further decreased by 75% upon GlcN treatment
(Fig. 5b). Atf6 overexpression also induced similar decreases
of Mef2a and Pgc1a expression compared with control cells
(data not shown). Treatment with a specific siRNA for Atf6
significantly inhibited the mRNA level of Atf6 in both
untreated and GlcN-treated cells (Fig. 5c). As expected, the
transfection of cells with an siRNA for a non-eukaryotic
gene, used as negative control, did not affect the upregulation
of Atf6 induced by GlcN (Fig. 5c). In addition, the siRNA for
Atf6 completely prevented GlcN-induced downregulation of
Glut4, Mef2a and Pgc1α (Fig. 5d). L6 cells were also
transfected with an siRNA for Shp (also known as Nr0b2).
As expected, the treatment with the siRNA for Shp
significantly inhibited the mRNA level of Shp in both
untreated and GlcN-treated cells (ESM Fig. 3a); by contrast,
it was not able to prevent the GlcN-induced downregulation
of Glut4, Mef2a and Pgc1α (ESM Fig. 3b). These data
indicate that the activation of Atf6 is responsible for the
impairment of Glut4 expression during GlcN-induced ER
stress through a mechanism independent of Shp activation.
Finally, to evaluate GlcN effects on human skeletal
muscle cells we used cultured human skeletal muscle cells
that display several features of mature skeletal muscle and
that have been previously used for studies of muscle
metabolism [20]. In differentiated human muscle cells,
GlcN induced a significant increase of both BIP/GRP78
and ATF6 mRNA levels (Fig. 6a, b), indicating that also the
human skeletal muscle cells were sensitive to GlcN-induced
ER stress. In addition, pretreatment with PBA completely
prevented the increase of both BIP/GRP78 and ATF6
mRNAs observed upon GlcN treatment (Fig. 6a, b),
confirming in human skeletal muscle cells the results
obtained in the rat cells. In human myotubes, GlcN
treatment reduced the expression of GLUT4 MEF2A and
PGC1α mRNAs (Fig. 6c–e), and completely inhibited the
uptake of 2-DG upon insulin stimulation compared with
control cells (Fig. 6f). Furthermore, human myotubes
treated with GlcN in the presence of PBA exhibited no
differences in the mRNA expression of both GLUT4 and its
upstream regulators MEF2A and PGC1α (Fig. 6c–e) and a
rescue of insulin-induced 2-DG uptake (Fig. 6f) compared
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mRNA was determined by real-time RT-PCR analysis of total RNA
isolated from myotubes, using Gapdh as internal standard. mRNA
levels in treated cells are relative expression units (REU) to those in
control (mean ± SD; n=5). ***p<0.001. b Time course of Glut4
mRNA in L6 cells treated with 7.5 mmol/l GlcN for the indicated
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with control cells. Thus, GlcN-induced ER stress impairs
insulin sensitivity also in human skeletal muscle, at least in
part by inhibiting GLUT4, MEF2A and PGC1α expression.
Discussion
Glucose toxicity may contribute to impaired insulin action
in diabetes [22]. A widely accepted hypothesis regarding
the mechanism responsible for glucose-induced insulin
resistance is that glucose toxicity is mediated by increased
flux of glucose into the HBP [17, 26, 27]. Other studies
have shown that GlcN, but not HG, causes impairment of
insulin-stimulated IRS-1 tyrosine phosphorylation and
phosphoinositide-3-kinase activation, and that defective
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protein kinase B activation by insulin is associated with
glucose- but not GlcN-mediated insulin resistance in
adipocytes [31]. Nevertheless, studies in several model
systems, including overexpression of GFAT and infusion/
treatment with GlcN have confirmed that increased flux
through HBP can lead to impaired glucose metabolism [27,
32]. Thus it seems likely that a role for the HBP in the
development of the metabolic syndrome and insulin
resistance will prevail. According to this, it has been
reported that GlcN infusion in rats induces insulin
resistance to glucose uptake at the level of both the whole
body and skeletal muscle [33]. Furthermore, GlcN induces
insulin resistance in vitro in skeletal muscle [34] and
adipose cells [35], by reducing the insulin-induced glucose
uptake.
Many investigators have suggested the reversible O-
acetylglucosamine modification of proteins as one possible
mechanism by which increased HBP activity may cause
insulin resistance and diabetes complications. However, the
causal relationship between increased flux through HBP
and insulin resistance has not been clearly established.
Recently, it has been reported that elevated GlcN levels
could interfere with correct protein folding in the ER,
inducing ER stress and impairment of cellular function in
hepatic cells, monocytes and smooth muscle cells [36]. On
the other hand, it has been described that ER stress and
UPR activation may play an important role in the
pathogenesis of type 2 diabetes [37], affecting both beta
cell function/survival [11–13] and obesity-induced periph-
eral insulin sensitivity in liver and adipose tissue [15, 28].
However, little is known about the role of ER stress in the
development of insulin resistance in skeletal muscle tissue.
A very recent study hypothesised a molecular convergence
of activated HBP and ER stress pathways leading to insulin-
resistance in L6 cells [38]. However, the causal link between
the O-glycosylation pathway and the ER stress pathway in
determining insulin resistance remained elusive. Indeed, cells
silenced for O-linked N-acetylglucosamine transferase, the
enzyme responsible for the addition of UDP-N-acetylglucos-
amine to Ser/Thr residues of proteins, and treated with GlcN
or HG, showed improved insulin-stimulated glucose uptake
without any effect on ER chaperone regulation [38].
In the present work, we suggest that ER stress may
represent the molecular link between GlcN and insulin
resistance in skeletal muscle cells. We show that high GlcN
concentrations, as well as the ER stress inducer Thap, cause
ER stress and the activation of the UPR in L6 rat skeletal
muscle cells, as demonstrated by increased expression of the
chaperone Bip/grp78 and of the transcription factor Atf6, the
phosphorylation of eIF2α and the increase of both the ex-
pression and splicing of the transcription factor XBP-1.
Furthermore, ER stress and UPR activation are induced by
GlcN in a model of human skeletal muscle cells [20],
suggesting that both rat and human skeletal muscle cells are
sensitive to GlcN-induced ER stress. More interestingly, HG
also induces ER stress in both L6 cells and human myotubes
(data not shown). Pretreatment of cells with azaserine, a non-
specific but commonly used inhibitor of GFAT [26, 27]
prevented HG-induced ER stress, suggesting that at least in
part HG levels cause ER stress through hexosamines
production. In addition, others [34] and we have shown that
L6 myotubes are insulin-resistant upon GlcN as well as HG
treatment, as demonstrated by the significant decrease in their
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capability to take up the glucose analogue 2-DG upon insulin
stimulation. To gain further insight into the mechanisms
leading to insulin resistance, Bailey and Turner [34] evaluated
GlcN-induced insulin-resistance in L6 myotubes using three
different insulin-sensitive acting agents. None of these agents
was able to prevent GlcN-induced insulin resistance [34],
suggesting that GlcN does not impair insulin sensitivity by
altering the upstream steps of insulin signalling. It has been
shown that inhibition of insulin-stimulated glucose uptake by
GlcN is due to intracellular ATP depletion in rat skeletal
muscle [31], adipocytes [39] and chondrocytes [40]. Howev-
er, in other cell types, ATP depletion by exposure to sodium
azide or dinitrophenol did not mimic the effects of GlcN to
induce insulin resistance [41]. Thus, ATP depletion is not the
sole mechanism underlying all of the effects of GlcN. Indeed,
we show that GlcN does not induce ATP depletion at the
concentrations used in this study, suggesting that GlcN effects
on both ER stress and insulin-resistance were not dependent
on ATP depletion in skeletal muscle cells. Interestingly, we
have found that pretreatment of both rat and human myotubes
with PBA or TUDCA, two chemical chaperones known to
prevent ER stress and the UPR activation in different cellular
systems [15, 28], completely prevents the effect of GlcN and
HG on both ER stress induction and insulin-induced glucose
uptake, suggesting that GlcN-induced insulin-resistance is, at
least in part, dependent on ER stress.
Glucose uptake into skeletal muscle is primarily medi-
ated by GLUT4 [29]. Since it is well documented that
insulin resistance in type 2 diabetes can be associated with
a marked reduction in GLUT4 expression [42] and/or
translocation [43], we hypothesised that GlcN-induced ER
stress might affect transcription of the gene for GLUT4 in
both rat and human muscle cells. Here we show that this is
the case, as both GLUT4 gene mRNA and protein levels
are decreased by 50% upon GlcN as well as upon Thap and
HG treatment. Both the human and the rat GLUT4 gene
promoter are regulated through the cooperative function of
two distinct regulatory elements, domain 1 and MEF2
domain, each required for the maximal transcription of
GLUT4 promoter. Domain 1 binds the transcription factor
GEF (GLUT4 enhancer factor); MEF2 domain binds
transcription factor isoforms MEF2A and MEF2D [42].
MEF2A and GEF associate and function together to
activate GLUT4 gene transcription [44]. Little is known
about GEF, whilst the role of MEF2A as the main regulator
of GLUT4 gene is well documented. Indeed, MEF2A
reduced activity correlates with decreased Glut4 transcrip-
tion in skeletal muscle of diabetic mice and its activity is
completely normalised after insulin treatment [45]. GLUT4
gene transcription can also be modulated in skeletal muscle
by other proteins, such as PGC1α [46]. PGC1α is a
coactivator of MEF2A. Indeed, MEF2D binds PGC1α,
recruiting this transcriptional coactivator to MEF2A [42].
Moreover, PGC1α expression is reduced in skeletal muscle
of prediabetic and diabetic individuals [47], and enhanced
GLUT4 mRNA expression coincides with increased
PGC1α mRNA in human skeletal muscle cell culture after
treatment with rosiglitazone [46]. Our data, obtained in
both rat and human myotubes, show that both GlcN- and
HG-induced GLUT4 inhibition is paralleled by a significant
decrease of both MEF2A and PGC1α gene mRNA
expression, indicating that GlcN-induced GLUT4 inhibition
is exerted very likely at the transcriptional level. Further-
more, mRNA stability of those genes does not appear to be
affected by GlcN-dependent ER stress (data not shown).
These observations were confirmed by ChIP and re-ChIP
experiments, showing a reduced binding of both MEF2A
and PGC1α to Glut4 promoter. Again, these effects appear
to be mediated by ER stress signalling, since PBA or
TUDCA pretreatment of myotubes is able to prevent
GLUT4, MEF2A and PGC1α gene inhibition following
both GlcN and Thap treatments. These observations
prompted us to consider the GlcN-induced insulin resis-
tance of skeletal muscle cells as a consequence of GLUT4
inhibition and, therefore, reduced membrane translocation
(data not shown). However, the contribution of additional
components known to be relevant to insulin resistance
caused by ER stress in adipocytes and skeletal muscle cells
[15, 38], such as JUN N-terminal kinase activation, cannot
be excluded. Different proteins have been described to be
activated by ER stress and to play a role in ER stress-
mediated transcriptional repression. Very recently, indeed,
ER stress-dependent activation of ATF6 has been reported
to impair insulin gene expression in INS-1 pancreatic beta
cells cultured in HG conditions or treated with different ER
stressors, via upregulation of SHP [30]. We demonstrate
that the overexpression of Atf6 is sufficient to inhibit the
expression of Glut4, Mef2a and Pgc1α both in basal
conditions and upon GlcN treatment and that the silencing
of Atf6 expression with a specific siRNA is sufficient to
completely prevent GlcN-induced downregulation of Glut4,
Mef2a and Pgc1α. This effect seems to be independent of
the upregulation of SHP, since its silencing does not modify
Glut4, Mef2a and Pgc1α in skeletal muscle cells upon
GlcN treatment.
It has been recently shown that ATF6 is responsible for
cystic fibrosis transmembrane conductance regulator tran-
scriptional repression by binding to its promoter [48]. Our
analysis of the minimal promoter region of Glut4, Mef2a
and Pgc1α (GenBank accession numbers: NC_005109.2,
NW_001084766.1 and NC_005113.2), using MatInspector,
identified several putative binding sites for ATF6 and for
other UPR regulatory factors. Further studies will be
necessary to understand if ATF6 could repress Glut4,
Mef2a and Pgc1α expression in our cell models through a
similar mechanism.
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In conclusion, in this work we show that GlcN- as well as
HG-induced ER stress causes insulin resistance in both
human and rat myotubes and impairs GLUT4 gene expres-
sion and insulin-induced glucose uptake via an ATF6-
dependent decrease of the GLUT4 regulator genes for
MEF2A and PGC1α. Interestingly, treatment with the
molecular chaperones PBA and TUDCA completely pre-
vents HG- and GlcN-induced UPR activation and restores
insulin sensitivity in myotubes. These findings are particu-
larly relevant for understanding the molecular mechanisms
of glucose toxicity in skeletal muscle and of the conse-
quences of ER stress in the pathogenesis of type 2 diabetes.
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